

# Julie A Lovshin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6784484/publications.pdf>

Version: 2024-02-01

52  
papers

2,245  
citations

331670

21  
h-index

214800

47  
g-index

53  
all docs

53  
docs citations

53  
times ranked

3592  
citing authors

#	ARTICLE	IF	CITATIONS
1	The association between physical activity time and neuropathy in longstanding type 1 diabetes: A cross-sectional analysis of the Canadian study of longevity in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108134.	2.3	5
2	Relationships between inflammation, hemodynamic function and RAAS in longstanding type 1 diabetes and diabetic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107880.	2.3	8
3	Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials. <i>Canadian Journal of Diabetes</i> , 2020, 44, 68-77.	0.8	15
4	Renal physiology of glucose handling and therapeutic implications. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, i3-i12.	0.7	46
5	Elevated plasma cyclic guanosine monophosphate may explain greater efferent arteriolar tone in adults with longstanding type 1 diabetes: A brief report. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 547-549.	2.3	1
6	Estimating GFR by Serum Creatinine, Cystatin C, and $\hat{I}^2$ -Microglobulin in Older Adults: Results From the Canadian Study of Longevity in Type 1 Diabetes. <i>Kidney International Reports</i> , 2019, 4, 786-796.	0.8	12
7	Risk factors for diabetic kidney disease in adults with longstanding type 1 diabetes: results from the Canadian Study of Longevity in Diabetes. <i>Renal Failure</i> , 2019, 41, 427-433.	2.1	4
8	Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes. <i>American Journal of Kidney Diseases</i> , 2019, 73, 786-796.	1.9	15
9	Association between uric acid, renal haemodynamics and arterial stiffness over the natural history of type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1388-1398.	4.4	12
10	Bone mineral density in patients with longstanding type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107324.	2.3	21
11	Sodium transport in diabetes: two sides to the coin. <i>Nature Reviews Nephrology</i> , 2019, 15, 125-126.	9.6	5
12	The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders. <i>European Neuropsychopharmacology</i> , 2019, 29, 137-146.	0.7	19
13	The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 575-583.	4.4	15
14	Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 273-280.	8.6	16
15	In Response. <i>Anesthesia and Analgesia</i> , 2018, 126, 1792-1793.	2.2	0
16	Adiposity Impacts Intrarenal Hemodynamic Function in Adults With Long-standing Type 1 Diabetes With and Without Diabetic Nephropathy: Results From the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetes Care</i> , 2018, 41, 831-839.	8.6	13
17	Response by Lytvyn et al to Letter Regarding Article, "Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials" <i>Circulation</i> , 2018, 137, 1984-1985.	1.6	1
18	Perioperative Considerations for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes. <i>Anesthesia and Analgesia</i> , 2018, 126, 699-704.	2.2	23

#	ARTICLE	IF	CITATIONS
19	Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting. Canadian Journal of Anaesthesia, 2018, 65, 143-147.	1.6	20
20	Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study. American Journal of Physiology - Renal Physiology, 2018, 314, F412-F422.	2.7	68
21	Diabetes Care Disparities in Long-standing Type 1 Diabetes in Canada and the U.S.: A Cross-sectional Comparison. Diabetes Care, 2018, 41, 88-95.	8.6	17
22	Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New. Canadian Journal of Diabetes, 2018, 42, 325-334.	0.8	11
23	The Relationships Between Retinopathy and Other Vascular Complications in Adults with Longstanding Diabetes: Results From the Canadian Study for Longevity in Type 1 Diabetes. Canadian Journal of Diabetes, 2018, 42, S50.	0.8	0
24	Atherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2018, 41, 2570-2578.	8.6	37
25	Sex differences in neuropathic pain in longstanding diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Journal of Diabetes and Its Complications, 2018, 32, 660-664.	2.3	22
26	Hyperfiltration, urinary albumin excretion, and ambulatory blood pressure in adolescents with Type 1 diabetes mellitus. American Journal of Physiology - Renal Physiology, 2018, 314, F667-F674.	2.7	41
27	In Response. Anesthesia and Analgesia, 2018, 127, 307-308.	2.2	0
28	Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes. JCI Insight, 2018, 3, .	5.0	38
29	Validity of a point-of-care nerve conduction device for polyneuropathy identification in older adults with diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. PLoS ONE, 2018, 13, e0196647.	2.5	13
30	Inadequate screening for retinopathy among recent immigrants with type 2 diabetes despite universal health care: A population-based study. Journal of Diabetes and Its Complications, 2017, 31, 664-668.	2.3	11
31	Neuropathy and presence of emotional distress and depression in longstanding diabetes: Results from the Canadian study of longevity in type 1 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 1318-1324.	2.3	37
32	Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?. Current Opinion in Nephrology and Hypertension, 2017, 26, 358-367.	2.0	27
33	Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1 $\pm$ 1-67 in Patients With Type 2 Diabetes. Diabetes Care, 2017, 40, 1073-1081.	8.6	82
34	Urinary adenosine excretion in type 1 diabetes. American Journal of Physiology - Renal Physiology, 2017, 313, F184-F191.	2.7	46
35	Response to Comment on Lovshin et al. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1 $\pm$ 1-67 in Patients With Type 2 Diabetes. Diabetes Care 2017;40:1073-1081. Diabetes Care, 2017, 40, e159-e160.	8.6	0
36	Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. Canadian Journal of Diabetes, 2017, 41, 524-535.	0.8	50

#	ARTICLE	IF	CITATIONS
37	Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors. <i>Canadian Journal of Ophthalmology</i> , 2017, 52, S4-S7.	0.7	0
38	Sodium Glucose Cotransporter-2 Inhibition in Heart Failure. <i>Circulation</i> , 2017, 136, 1643-1658.	1.6	340
39	Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders. <i>European Neuropsychopharmacology</i> , 2017, 27, 1153-1162.	0.7	49
40	Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study. <i>Journal of Affective Disorders</i> , 2017, 207, 114-120.	4.1	110
41	Lower corneal nerve fibre length identifies diabetic neuropathy in older adults with diabetes: results from the Canadian Study of Longevity in Type 1 Diabetes. <i>Diabetologia</i> , 2017, 60, 2529-2531.	6.3	14
42	GLP-1R Agonists and Endothelial Dysfunction: More Than Just Glucose Lowering?. <i>Diabetes</i> , 2015, 64, 2319-2321.	0.6	14
43	Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 132-139.	8.6	137
44	Can two be better than one? Dual RAS blockade in patients with type 2 diabetes and overt nephropathy in the age of ONTARGET and ALTITUDE. <i>Hypertension Research</i> , 2014, 37, 4-6.	2.7	1
45	Blood Pressure-Lowering Effects of Incretin-Based Diabetes Therapies. <i>Canadian Journal of Diabetes</i> , 2014, 38, 364-371.	0.8	35
46	Metabolic Disease Puts Up a Fight: Are diet and exercise helpful for the heart?. <i>Nature Medicine</i> , 2013, 19, 1216-1217.	30.7	2
47	Clinical inertia—a barrier to effective management of T2DM. <i>Nature Reviews Endocrinology</i> , 2013, 9, 635-636.	9.6	18
48	Incretin-based therapies for type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2009, 5, 262-269.	9.6	573
49	Glucagon-like Peptide (GLP)-2 Action in the Murine Central Nervous System Is Enhanced by Elimination of GLP-1 Receptor Signaling. <i>Journal of Biological Chemistry</i> , 2001, 276, 21489-21499.	3.4	98
50	New frontiers in the biology of GLP-2. <i>Regulatory Peptides</i> , 2000, 90, 27-32.	1.9	58
51	New Developments in the Biology of the Glucagon-Like Peptides GLP-1 and GLP-2. <i>Annals of the New York Academy of Sciences</i> , 2000, 921, 226-232.	3.8	26
52	Ontogeny of the Glucagon-Like Peptide-2 Receptor Axis in the Developing Rat Intestine. <i>Endocrinology</i> , 2000, 141, 4194-4201.	2.8	18